Abstract
Age-related diseases pose as an enormous problem on aging populations of the world. Despite the fact that many advances have been made on understanding of the neurodegeneration, there is still no cure available for the agerelated brain disorders. Sirtuins are NAD-dependent protein deacetylases that were shown to have beneficial effects against age-related diseases. SIRT1 and SIRT2 have been studied mostly in terms of neurodegenerative diseases and seem to have opposite effects. According to the recent findings, activators of SIRT1 and inhibitors of SIRT2 would benefit the brain from neurodegeneration. Despite the enormous amount of research that has been conducted so far, there is still no cure or treatment for almost all of the neurodegenerative disorders. In addition, the mechanisms underlying brain aging and also the link between aging and neurodegeneration are not understood. This review focuses on the role of sirtuins as possible drug targets for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s Diseases.
Keywords: Alzheimer’s disease, aging, Parkinson’s disease, sirtuins, neurodegeneration, therapeutic targets.
Current Drug Targets
Title:Sirtuins as Possible Targets in Neurodegenerative Diseases
Volume: 14 Issue: 6
Author(s): Gizem Donmez
Affiliation:
Keywords: Alzheimer’s disease, aging, Parkinson’s disease, sirtuins, neurodegeneration, therapeutic targets.
Abstract: Age-related diseases pose as an enormous problem on aging populations of the world. Despite the fact that many advances have been made on understanding of the neurodegeneration, there is still no cure available for the agerelated brain disorders. Sirtuins are NAD-dependent protein deacetylases that were shown to have beneficial effects against age-related diseases. SIRT1 and SIRT2 have been studied mostly in terms of neurodegenerative diseases and seem to have opposite effects. According to the recent findings, activators of SIRT1 and inhibitors of SIRT2 would benefit the brain from neurodegeneration. Despite the enormous amount of research that has been conducted so far, there is still no cure or treatment for almost all of the neurodegenerative disorders. In addition, the mechanisms underlying brain aging and also the link between aging and neurodegeneration are not understood. This review focuses on the role of sirtuins as possible drug targets for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s Diseases.
Export Options
About this article
Cite this article as:
Donmez Gizem, Sirtuins as Possible Targets in Neurodegenerative Diseases, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060004
DOI https://dx.doi.org/10.2174/1389450111314060004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Solvent-Free Synthesis of 4,5-Dihydropyrano[c]chromene Derivatives Over TiO<sub>2</sub> Nanoparticles as an Economical and Efficient Catalyst
Current Catalysis Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Exploring the Role of Stem Cell Therapy in Treating Neurodegenerative Diseases: Challenges and Current Perspectives
Current Stem Cell Research & Therapy A Translational View of Peptide Treatment of Neurological Disorders
Current Medicinal Chemistry Patent Selections
Recent Patents on Food, Nutrition & Agriculture Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy SS31, a Small Molecule Antioxidant Peptide, Attenuates β-Amyloid Elevation, Mitochondrial/Synaptic Deterioration and Cognitive Deficit in SAMP8 Mice
Current Alzheimer Research Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists
Current Medicinal Chemistry Clinical Utility of Soluble CD163 and its Diagnostic and Prognostic Value in a Variety of Neurological Disorders
Mini-Reviews in Medicinal Chemistry Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Autophagy Modulators and Neuroinflammation
Current Medicinal Chemistry The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders
Current Neuropharmacology The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases
Current Drug Targets The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy
Current Medicinal Chemistry